TARSUS PHARMACEUTICALS, INC. Income Tax Expense
TARSUS PHARMACEUTICALS, INC. (TARS) reported Income Tax Expense of $2.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2026-06-30 was $2.72M.
- TARSUS PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2026-03-31 was $2.35M.
- TARSUS PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2025-06-30 was $0.00.
- TARSUS PHARMACEUTICALS, INC. income tax expense (benefit) for the quarter ending 2025-03-31 was $0.00.
- TARSUS PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2025 was $2.06M.
- TARSUS PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2024 was $0.00.
- TARSUS PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2023 was $0.00.
- TARSUS PHARMACEUTICALS, INC. income tax expense (benefit) for fiscal 2022 was -$4.00K, a 107.27% decline from fiscal 2021.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.72M 10-Q · filed 2026-08-06 | $5.07M 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $2.35M 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $2.06M 10-K · filed 2026-02-23 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-23 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | -$5.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | -$5.00K derived: sum of 3 quarters · filed 2025-02-25 | -$5.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$5.00K derived: sum of 2 quarters · filed 2025-02-25 | -$5.00K derived: sum of 3 quarters · filed 2025-02-25 | -$4.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | -$5.00K 10-Q · filed 2023-11-09 | -$5.00K derived: sum of 2 quarters · filed 2023-11-09 | -$4.00K 10-Q · filed 2023-11-09 | $50.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 | $1.00K 10-Q · filed 2023-08-10 | $55.00K derived: sum of 3 quarters · filed 2023-08-10 | -$286.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.00K 10-Q · filed 2023-05-09 | $55.00K derived: sum of 2 quarters · filed 2023-05-09 | -$286.00K derived: sum of 3 quarters · filed 2023-05-09 | -$257.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$287.00K derived: sum of 2 quarters · filed 2023-03-17 | -$258.00K derived: sum of 3 quarters · filed 2023-03-17 | $55.00K 10-K · filed 2023-03-17 |
| 2021-09-30 | -$341.00K 10-Q · filed 2022-11-09 | -$312.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.00K 10-Q · filed 2022-11-09 | $1.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $29.00K 10-Q · filed 2022-08-11 | $342.00K 10-Q · filed 2022-08-11 | $342.00K derived: sum of 3 quarters · filed 2022-08-11 | $343.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $313.00K 10-Q · filed 2022-05-11 | $313.00K derived: sum of 2 quarters · filed 2022-05-11 | $314.00K derived: sum of 3 quarters · filed 2022-05-11 | $314.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.00K derived: sum of 2 quarters · filed 2022-03-14 | $1.00K derived: sum of 3 quarters · filed 2022-03-14 | $1.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-10 | $1.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.00K 10-Q · filed 2021-11-10 | $1.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | $0.00 derived: sum of 3 quarters · filed 2021-08-05 | $0.00 derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | $0.00 derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $0.00 derived: sum of 2 quarters · filed 2021-03-31 | $1.00K 10-K · filed 2021-03-31 | |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-25 | $1.00K 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |